Updated:
Xeris Pharmaceuticals
Xeris Pharmaceuticals is a pharmaceutical company based in Chicago, United States, founded in 2005. It develops and commercializes ready-to-use, liquid-stable...
Xeris Pharmaceuticals
Xeris Pharmaceuticals is a pharmaceutical company based in Chicago, United States, founded in 2005. It develops and commercializes ready-to-use, liquid-stable injectables using its novel formulation technology platforms. The company has secured $115.5 million in total funding.
General information
Firm type
Biopharmaceutical
Year founded
2005
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Additional offices
Chicago, United States
Sector focus
Frequently asked questions
What is the investment focus of Xeris Pharmaceuticals?
Xeris Pharmaceuticals appears to focus on pharmaceutical and biotech investments, with offices in Tokyo and Chicago indicating a cross-border strategy between Japan and the United States. Specific portfolio companies or sectors beyond healthcare are not publicly disclosed.
How is Xeris Pharmaceuticals structured?
Public records indicate the firm operates from Japan and the United States, but its legal structure — whether as a family office, asset manager, or holding company — is not specified in available sources.
Does Xeris Pharmaceuticals invest in early-stage or late-stage companies?
No public information details the investment stage preferences of Xeris Pharmaceuticals. The firm's focus on pharmaceuticals could imply involvement across development stages, but this is speculative without confirmed data.
What is the geographic focus of Xeris Pharmaceuticals?
The firm maintains offices in Tokyo (Japan) and Chicago (United States), suggesting investments primarily in these two regions. Broader geographic scope is not documented.
Who are the key principals at Xeris Pharmaceuticals?
No named principals or leadership team members for Xeris Pharmaceuticals are available in public sources. The firm's management structure remains undisclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: